| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 07/03/2003 | US20030124150 Kit for reducing aching |
| 07/03/2003 | US20030124142 Immunomodulatory constructs and their uses |
| 07/03/2003 | US20030124129 Angiopoietin-2 specific binding agents |
| 07/03/2003 | US20030124123 Also an IL-12 anti-idiotype antibody to the antibody |
| 07/03/2003 | US20030124116 Antibodies binding to polypeptides encoded by the genes |
| 07/03/2003 | US20030124114 Genes that encode cell surface molecules with conserved IgV and mucin domains; diagnosis or staging of cancer; treatment of an immunological disorder; detecting a predisposition to asthma |
| 07/03/2003 | US20030124113 Human apoptosis associated proteins |
| 07/03/2003 | US20030124101 Sir2alpha-based therapeutic and prophylactic methods |
| 07/03/2003 | US20030124100 Includes an endothelial specific enhancer element; especially modifications of the PPE promoter, which enhance its expression in response to hypoxia and angiogenesis. |
| 07/03/2003 | US20030124092 IL-17 like molecules and uses thereoflike molecules and uses thereof |
| 07/03/2003 | US20030124086 Polymer conjugates of opioid antagonists |
| 07/03/2003 | US20030124075 Use of a composition containing at least one oxidation-sensitive hydrophilic active principle and at least one N-vinylimidazole polymer or copolymer |
| 07/03/2003 | US20030124056 Carrier molecules |
| 07/03/2003 | CA2849201A1 Adipose-derived cell processing unit |
| 07/03/2003 | CA2486930A1 Anti-tirc7 antibodies in therapy of inflammatory diseases |
| 07/03/2003 | CA2486689A1 Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| 07/03/2003 | CA2471400A1 Vaginal delivery of drugs |
| 07/03/2003 | CA2471373A1 Modified tridegins, their preparation and their use as transglutaminase inhibitors |
| 07/03/2003 | CA2471140A1 Antibodies that immunospecifically bind to trail receptors |
| 07/03/2003 | CA2471107A1 Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| 07/03/2003 | CA2471089A1 Pyridoquinoxaline antivirals |
| 07/03/2003 | CA2471081A1 Formulation & dosage form for the controlled delivery of therapeutic agents |
| 07/03/2003 | CA2470995A1 Methods of treating bacterial infections in dogs and cats |
| 07/03/2003 | CA2470964A1 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors |
| 07/03/2003 | CA2470938A1 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/03/2003 | CA2470900A1 Compositions and methods for the diagnosis and treatment of tumor |
| 07/03/2003 | CA2470844A1 Novel compositions and methods for cancer |
| 07/03/2003 | CA2470612A1 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| 07/03/2003 | CA2470594A1 Leptin proteins |
| 07/03/2003 | CA2470576A1 Methods for slowing senescence and treating and preventing diseases associated with senescence |
| 07/03/2003 | CA2470443A1 Pharmaceutical compositions based on azetidine derivatives |
| 07/03/2003 | CA2470063A1 Parmaceutical agents and methods for tissue and vascular regeneration |
| 07/03/2003 | CA2469904A1 Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| 07/03/2003 | CA2469894A1 Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| 07/03/2003 | CA2469370A1 Adipose-derived cell processing unit |
| 07/03/2003 | CA2469047A1 Tempamine compositions and methods of use |
| 07/03/2003 | CA2468083A1 Use of heterocyclic carboxamides to treat anemia |
| 07/03/2003 | CA2466483A1 Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| 07/03/2003 | CA2462670A1 Sperm-specific cation channel, catsper2, and uses therefor |
| 07/03/2003 | CA2462587A1 Modulating insulin receptor signaling through targeting facl |
| 07/03/2003 | CA2453810A1 Mutant proteinase inhibitors and uses thereof |
| 07/02/2003 | EP1323440A1 Peritoneal dialysates |
| 07/02/2003 | EP1323433A1 Compositions for preventing urinary calculus |
| 07/02/2003 | EP1323431A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 07/02/2003 | EP1323430A2 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
| 07/02/2003 | EP1323423A1 Combined preparations comprising anthracycline derivatives |
| 07/02/2003 | EP1322954A1 Method for treatment of insulin resistance in obesity and diabetes |
| 07/02/2003 | EP1322778A2 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| 07/02/2003 | EP1322769A2 Protein phosphatases |
| 07/02/2003 | EP1322768A2 Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides |
| 07/02/2003 | EP1322760A2 G-protein coupled receptors |
| 07/02/2003 | EP1322759A2 Potassium channel interactors and uses therefor |
| 07/02/2003 | EP1322757A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 07/02/2003 | EP1322755A1 Human and mouse targeting peptides identified by phage display |
| 07/02/2003 | EP1322656A2 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 07/02/2003 | EP1322599A2 Hiv integrase inhibitors |
| 07/02/2003 | EP1322411A1 Colloidal suspension of submicronic particles for carrying active principles and their mode of preparation |
| 07/02/2003 | EP1322351A1 Coated medical devices |
| 07/02/2003 | EP1322334A2 Methods of inducing cancer cell death and tumor regression |
| 07/02/2003 | EP1322333A2 Composition for combined use of aromatase inhibitors |
| 07/02/2003 | EP1322332A2 Compositions and methods for inhibition of hiv-1 infection |
| 07/02/2003 | EP1322328A2 Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 07/02/2003 | EP1322325A1 Inhibiting hepatitis c virus processing and replication |
| 07/02/2003 | EP1322324A2 Methods for treating muscle injuries |
| 07/02/2003 | EP1322323A1 Thionin as an antineoplastic and immunostimulant |
| 07/02/2003 | EP1322319A1 Use of il-8 protein modulators in the treatment of viral infections |
| 07/02/2003 | EP1322318A1 Use of probiotic lactic acid bacteria for balancing the skin's immune system |
| 07/02/2003 | EP1322314A2 Treatment of diabetes mellitus by inhibition of mitochondrial calcium/sodium antiporter |
| 07/02/2003 | EP1322312A1 Use of medicaments |
| 07/02/2003 | EP1322311A1 Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist |
| 07/02/2003 | EP1322310A1 Alpha v integrin receptor antagonists |
| 07/02/2003 | EP1322307A1 Methods for treating cell proliferative disorders and viral infections |
| 07/02/2003 | EP1322306A2 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent |
| 07/02/2003 | EP1322301A1 Combination particles for the treatment of asthma |
| 07/02/2003 | EP1322300A1 Inhalation particles incorporating a combination of two or more active ingredients |
| 07/02/2003 | EP1322299A2 Composition for the transdermal delivery of fentanyl |
| 07/02/2003 | EP1322293A1 Modified release formulation |
| 07/02/2003 | EP1322292A2 Microparticle compositions and methods for the manufacture thereof |
| 07/02/2003 | EP1322289A1 Spray drying process and compositions of fenofibrate |
| 07/02/2003 | EP1322287A2 Microparticles for delivery of the heterologous nucleic acids |
| 07/02/2003 | EP1242092B1 Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug |
| 07/02/2003 | EP1239885A4 Interventions to mimic the effects of calorie restriction |
| 07/02/2003 | EP1150666A4 Stimulating neutrophil function to treat inflammatory bowel disease |
| 07/02/2003 | EP1143994B1 Use of apoptosis inducing agents in the preparation of a medicament for the treatment of (auto)immune diseases |
| 07/02/2003 | EP0975327B1 Use of 5ht3 antagonists for promoting intestinal lavage |
| 07/02/2003 | EP0954292B1 Pharmaceutical formulations with delayed drug release |
| 07/02/2003 | EP0826043B1 Methods for modulating t cell survival by modulating bcl-xl protein level |
| 07/02/2003 | EP0810879B1 Preparation and use of a specific gaba-aalpha5 receptor ligand for treatment of alzheimer's disease |
| 07/02/2003 | EP0779810B1 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes |
| 07/02/2003 | EP0732875B1 Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5) |
| 07/02/2003 | EP0626864B1 Topical composition containing hyaluronic acid and nsaids |
| 07/02/2003 | CN1427891A Anti-EGFRvIII scFv with improved cytotoxi city and yield, immunotoxins based thereon, and methods of use thereof |
| 07/02/2003 | CN1427844A Bis-(N,N'-bis-(2-haloethyl) amino) phosphoramidates as antitumor agents |
| 07/02/2003 | CN1427826A Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl IV, processes for their preparation, and their use |
| 07/02/2003 | CN1427825A Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands |
| 07/02/2003 | CN1427730A Medicinal aerosol formulation |
| 07/02/2003 | CN1427722A Method for treatment or prevention of flavivirus infections using nucleoside analogues |
| 07/02/2003 | CN1427720A Metabotropic glutamate receptor antagonists for treating tolerance and dependency |
| 07/02/2003 | CN1427719A Use of substituted acryloyl distamycin derivatives in treatment of tumors associated with high levels of glutathione |
| 07/02/2003 | CN1427718A Pharmaceutical compounds for treating COPD |